#Canada #Toronto #RamSoft #MammoScreen #Therapixel

RamSoft and Therapixel Forge Partnership for Enhanced Breast Imaging Solutions

In a groundbreaking announcement made during the SIIM 2025 Annual Meeting, RamSoft, a leader in cloud-based RIS/PACS platforms, has teamed up with Therapixel, an acclaimed medical imaging AI innovator, to deliver an integrated AI-powered breast imaging solution. This partnership aims to revolutionize the cancer detection process by embedding Therapixel's cutting-edge MammoScreen® software directly into RamSoft's existing platforms, PowerServer™ and OmegaAI®.

The integration allows RamSoft customers to access advanced AI capabilities designed to streamline workflows and enhance diagnostic accuracy in breast imaging. As healthcare professionals strive to provide better service, leveraging the latest technology becomes essential, and this collaboration marks a significant step toward achieving that goal.

Enhanced Workflow and Improved Diagnostic Confidence

Vijay Ramanathan, CEO and Co-Founder of RamSoft, expressed excitement about the partnership, citing that the integration of MammoScreen® represents a crucial development in improving diagnostic confidence and productivity for radiologists. The new system enhances workflow through three key features:
1. Pre-check: This capability ensures optimal image quality and confirms essential patient information prior to the diagnostic reading, helping radiologists prepare their assessments more efficiently.
2. Cancer Detection: MammoScreen® utilizes AI algorithms to deliver comprehensive analyses that detect and characterize lesions, taking into account previous imaging results and assessing breast density. This multifaceted approach aims to deliver a more accurate diagnosis at earlier stages of detection.
3. Pre-reporting: The software automatically populates structured results into existing reporting systems, which significantly reduces the time and effort traditionally spent on documentation, allowing radiologists to focus more on patient care.

Proven Success in Clinical Studies

Clinical evaluations of MammoScreen® have showcased remarkable results. One study indicated an 8% increase in sensitivity and a 2% increase in specificity for radiologist performance. Furthermore, it was noted that the solution successfully identified screen-detectable cancers an astonishing 42% of the time one year in advance and 38.5% two years prior, highlighting the formidable potential of integrated AI technology.

"At Therapixel, we have always aimed to empower radiologists with technology that enhances their accuracy and confidence," said Matthieu Leclerc-Chalvet, CEO of Therapixel. He emphasized that the direct embedding of MammoScreen® within existing PACS platforms simplifies the user experience and maximizes clinical value, particularly important in women's health.

Commitment to Innovative Healthcare Solutions

This partnership not only demonstrates a commitment to innovation for both companies but also emphasizes the importance of open platforms in popularizing advanced medical AI tools. By providing MammoScreen® as a turnkey solution within current PACS workflows, radiologists can now leverage cutting-edge technology without needing additional systems or interfaces.

As part of their ongoing dedication to improving women's health services, RamSoft and Therapixel believe that this integration will provide radiologists with the essential tools needed to enhance diagnostic workflows, ultimately leading to improved patient outcomes.

In conclusion, the collaboration between RamSoft and Therapixel signifies a progressive leap in breast imaging technology, utilizing AI to deliver faster diagnoses and better patient care. It highlights the potential for future innovations in medical imaging and sets a new standard for excellence in the industry, paving the way for more integrated healthcare solutions that empower both professionals and patients alike.